文献速递白血病

儿童ABL类融合B细胞急性淋巴细胞白血病在酪氨酸激酶抑制剂前时代的多中心回顾性队列研究结局

Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
PubMed 文献 · Lancet Haematol · 2020-12-22

该多中心回顾性队列研究纳入2000年至2018年间未接受酪氨酸激酶抑制剂一线治疗的122例ABL类融合B细胞急性淋巴细胞白血病患儿,分析其基线特征与结局。诱导治疗结束时MRD≥10^-2预示不良结局。研究提示不含酪氨酸激酶抑制剂的方案疗效不佳,为评估一线酪氨酸激酶抑制剂治疗获益提供参考。

要点

  • 接受HSCT者5年累积复发率低于未移植者,但EFS和OS无差异。

核心结论

  • 不含酪氨酸激酶抑制剂的方案治疗ABL类融合B-ALL患儿结局较差,尽管使用了高危化疗和频繁HSCT。

研究设计与样本

  • 多中心回顾性队列研究,纳入2000年10月3日至2018年8月28日间14个研究组(欧洲、北美、亚太)的122例1-18岁初诊ABL类融合B-ALL患儿,均未接受TKI一线治疗。

主要发现

  • 122例中PDGFRB融合阳性64例(52%),ABL1阳性40例(33%),CSF1R阳性10例(8%),ABL2阳性8例(7%)。
  • 诱导治疗结束时MRD≥10^-2者61/93例(66%),在ABL2融合(6/7,86%)和PDGFRB融合(43/49,88%)中最常见。

临床怎么用

  • 对于ABL类融合B-ALL患儿,诱导后MRD≥10^-2提示不良结局,应加强监测和考虑强化治疗。
  • HSCT可降低复发风险但未改善EFS或OS,需权衡利弊。
  • 研究结果支持开展一线TKI治疗的临床试验以评估获益。

局限性

  • 回顾性研究设计,可能存在选择偏倚和信息偏倚。
  • 未包含接受TKI治疗的患者,无法直接评估TKI疗效。
  • HSCT组与未HSCT组比较非随机,存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ABL-class fusion genes other than BCR-ABL1 have been identified in approximately 3% of children with newly diagnosed acute lymphocytic leukaemia, and studies suggest that leukaemic cells carrying ABL-class fusions can be targeted successfully by tyrosine-kinase inhibitors. We aimed to establish the baseline characteristics and outcomes of paediatric patients with ABL-class fusion B-cell acute lymphocytic leukaemia in the pre-tyrosine-kinase inhibitor era. METHODS: This multicentre, retrospective, cohort study included paediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion (ABL1 fusion-positive, ABL2 fusion-positive, CSF1R fusion-positive, and PDGFRB fusion-positive) B-cell acute lymphocytic leukaemia enrolled in clinical trials of multidrug chemotherapy done between Oct 3, 2000, and Aug 28, 2018, in which tyrosine-kinase inhibitors had not been given as a first-line treatment. Patients from 14 European, North American, and Asia-Pacific study groups of the Ponte di Legno group were included. No patients were excluded, and patients were followed up by individual study groups. Through the Ponte di Legno group, we collected data on the baseline characteristics of patients, including IKZF1, PAX5, and CDKN2A/B deletion status, and whether haematopoietic stem cell transplantation (HSCT) had been done, as well as treatment outcomes, including complete remission, no response, relapse, early death, and treatment-related mortality, response to prednisone, and minimal residual disease (MRD) at end of induction therapy. 5-year event-free survival and 5-year overall survival were estimated by use of Kaplan-Meier methods, and the 5-year cumulative incidence of relapse was calculated by use of a competing risk model. FINDINGS: We identified 122 paediatric patients with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukaemia (77 from European study groups, 25 from North American study groups, and 20 from Asia-Pacific study groups). 64 (52%) of 122 patients were PDGFRB fusion-positive, 40 (33%) were ABL1 fusion-positive, ten (8%) were CSF1R fusion-positive, and eight (7%) were ABL2 fusion-positive. In all 122 patients, 5-year event-free survival was 59·1% (95% CI 50·5-69·1), 5-year overall survival was 76·1% (68·6-84·5), and the 5-year cumulative incidence of relapse was 31·0% (95% CI 22·4-40·1). MRD at the end of induction therapy was high (≥10-2 cells) in 61 (66%) of 93 patients, and most prevalent in patients with ABL2 fusions (six [86%] of 7 patients) and PDGFRB fusion-positive B-cell acute lymphocytic leukaemia (43 [88%] of 49 patients). MRD at the end of induction therapy of 10-2 cells or more was predictive of an unfavourable outcome (hazard ratio of event-free survival in patients with a MRD of ≥10-2vs those with a MRD of <10-2 3·33 [95% CI 1·46-7·56], p=0·0039). Of the 36 (30%) of 119 patients who relapsed, 25 (69%) relapsed within 3 years of diagnosis. The 5-year cumulative incidence of relapse in 41 patients who underwent HSCT (17·8% [95% CI 7·7-31·3]) was lower than in the 43 patients who did not undergo HSCT (45·1% [28·4-60·5], p=0·013), but event-free survival and overall survival did not differ between these two groups. INTERPRETATION: Children with ABL-class fusion B-cell acute lymphocytic leukaemia have poor outcomes when treated with regimens that do not contain a tyrosine-kinase inhibitor, despite the use of high-risk chemotherapy regimens and frequent HSCT upon first remission. Our findings provide a reference for evaluating the potential benefit of first-line tyrosine-kinase inhibitor treatment in patients with ABL-class fusion B-cell acute lymphocytic leukaemia. FUNDING: The Oncode Institute, Pediatric Cancer Foundation Rotterdam, Dutch Cancer Society, Kika Foundation, Deutsche Krebshilfe, Blood Cancer UK, Associazione Italiana per la Ricerca sul Cancro, Cancer Australia, National Cancer Institute, National Institute of Health, and St Baldrick's Foundation.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. den Boer ML, Cario G, Moorman AV, et al. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematol. 2020. PMID: 33357483. doi:10.1016/S2352-3026(20)30353-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。